BIOXYNE LIMITED — Capital/Financing Update 2012

Mar 14, 2012

==> picture [218 x 50] intentionally omitted <==

==> picture [36 x 36] intentionally omitted <==

Probiomics Limited ABN 97 084 464 193

The Australian Securities Exchange Companies Announcement Office SYDNEY NSW 2000

15 March, 2012

Suite 1 A, Level 2 802 Pacific Highway Gordon NSW 2072

P: +61 2 9844 5422 F: +61 2 9844 5445 W: www.probiomics.com.au

Dear Sir/Madam

Notification of Amendment to Timetable for commencement of Re-admission to Official List

Probiomics (“Company”, ASX: PCC) expects that the re-admission of the Company to the ASX Official List, and the re-commencement of trading in the Company’s securities on ASX, will be completed in accordance with the following indicative timetable:

Event	Originally proposeddate	Amended date
Close of Public Offer Period	6 February, 2012	27 February, 2012
Close of Takeover Bid Period	16 March, 2012	23 March, 2012
Last day for registration of transfers in the Company’ssecurities on a pre-Share Consolidation basis	-	23 March, 2012
Share Consolidation on a 1:20 basis	21 March, 2012	27 March, 2012
Issue of:•Public Offer Shares and Public Offer Options;•Bid Consideration, being Consolidated ProbiomicsShares and Replacement Probiomics Options; and•Director Options and Probiomics PerformanceExecutive Options	19 March, 2012	28 March, 2012
Completion of dispatch of new holding statements torelevant Probiomics securityholders to reflect:•the issue of the Probiomics Securities referred to inthe immediately above row; and•changes in holdings of Probiomics Securities as aresult of the Share Consolidation	28 March, 2012	29 March, 2012
Re-commencement of quotation of the Company’sshares and options on the ASX Official List	-	4 April, 2012
Change in the Company’s name to “Bioxyne Limited”becomes effective	30 March, 2012	10 April, 2012

==> picture [218 x 51] intentionally omitted <==

As at the date of this announcement, there is no proposal to alter the date of any other Event referred to in the “Important Dates” at the commencement of the Bidder’s Statement issued by the Company and dated 13 December, 2011.

The Company however reserves the right to vary the date of any Event referred to in the “Important Dates”, including the date of any of the Events referred to in the table immediately above.

Yours sincerely,

==> picture [127 x 56] intentionally omitted <==

A Jairath, Company Secretary

Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC[® ]

PCC[®] has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics’ commercial objective is to earn royalties from licensing PCC[®] to distribution companies selling products in global markets.